Canatu has granted a commercial production license for the first CNT100 SEMI reactor to Korean semiconductor company FINE SEMITECH CORPORATION (hereinafter “FST”). The license authorizes FST as the licensee to mass-produce CNT pellicle membranes using the CNT100 SEMI reactor, which will be operated by FST. FST will pay Canatu a one-time license fee for the commercial production rights.
The value of the one-time license fee for commercial production of CNT pellicle membranes is classified within the lower half of the “Medium” (1.0- 5.0M€) category under Canatu’s disclosure policy. The related revenue will be recognized in Q4/2025.
The commencement of commercial production will also create two new sources of future revenue streams for Canatu:
- Sales of proprietary consumables used in the CNT manufacturing process by Canatu
- Royalties payable to Canatu on each CNT pellicle sold by FST to its end customers
The materialization of such future revenue streams is subject to uncertainties, as such revenue streams are inherently dependent on FST and its end customers, and are therefore not fully within Canatu’s control.
Juha Kokkonen, CEO of Canatu, commented: “This marks a significant milestone, bringing our customer closer to high-volume mass production of CNT pellicle membranes. It also validates the maturity of CNT pellicle technology and demonstrates market demand for CNT pellicles.”
The first CNT100 SEMI reactor was shipped to FST in September 2024. In July 2025, Canatu announced that the reactor and associated post-processing equipment had passed the customer approval (Site Acceptance Test, SAT). The mass production license now granted is part of the agreed roadmap toward commercial deployment.
